CCM-405

CCM-405 is a novel, orally bioavailable small molecule inhibitor targeting FMS-like tyrosine kinase 3 (FLT3), developed for the treatment of acute myeloid leukemia (AML). It is designed to overcome resistance mutations in both the FLT3 internal tandem duplication (ITD) juxtamembrane domain and tyrosine kinase domain (TKD), including clinically significant mutations such as D835Y and F691L. Preclinical data indicate that CCM-405 demonstrates significantly greater efficacy than current-generation FLT3 inhibitors like gilteritinib, both in the presence and absence of resistance mutations. The drug is being advanced toward investigational new drug (IND) filing for clinical trials in newly diagnosed and relapsed/refractory FLT3-positive AML[1][2][4].